ClinicalTrials.gg
RecruitingNCT05640024Updated Dec 7, 2022

Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors

An observational study in Ovarian Cancer, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Yonsei University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
54
Ages
19 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ovarian Neoplasms by Yonsei University — 4 open to participants now, 6 under way, none of them phase 3. Ovarian Neoplasms · Yonsei University.

Started
2022
the only one that year
Observational
5 of 14
2 open now
Registered
10th of 14
by date

Among the 14 studies in Ovarian Neoplasms by Yonsei University, this one is the only one that started in 2022, is one of 5 observational ones, and was the 10th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

4 of the 14 studies in Ovarian Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ovarian Neoplasms by Yonsei University, or all of them as a file.
02

Study summary

Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status are unknown. Previous study, we analyzed the dynamic immunological changes in peripheral T cells during PARP inhibitor maintenance therapy and found predictive biomarkers. The purpose of this study is to prospectively validate the biomarkers for predicting response to PAPR inhibitors in ovarian cancer. We collect serial blood samples (before initiation of therapy and after 1, 3, and 6 months) in ovarian cancer patients who receive PARP inhibitor and analyze immunological characteristics of peripheral CD8 and regulatory T cells. Through assessment of the baseline properties and dynamic changes in T cells, we aim to validate the predictive biomarker and develope promising novel targets to enhancing survival outcomes of high-risk patients.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Ovarian cancer patients who receive PARP inhibitor

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological diagnosis of epithelial ovarian cancer, 2. Presence of germline or somatic BRCA mutational status result, 3. Advanced or recurrent ovarian cancer patients who responded to their most recent platinum-based chemotherapy and plan to start PARPi (olaparib or niraparib) maintenance therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients who refuse to participate, 2. Patients having difficulty understanding the protocol due to language barrier
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
54 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Validation of biomarkers for predicting response to PAPR inhibitor

    Investigators will utilize baseline peripherap blood mononuclear cells (PBMCs) to validate predictive biomarkers to PARP inhibitor. Response to PAPR inhibitor was defined by BRCA1/2 status and duration of PAPR inhibitor treatment.

    Time frame: The primary endpont will be accessed 12 months after last patient registration.

Secondary outcomes

  1. Identify dynamic immunological changes during PAPR inhibitor therapy

    Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy.

    Time frame: Immunological changes (Time Frame: 6 months

  2. Identify promising novel targets to enhance survivla outcomes of high-risk pateints in PAPR inhibitor therapy.

    Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy.

    Time frame: Identify promising novel targets (Time Frame: 12 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Oct 2025, 35 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 35 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2022
First posted
Dec 7, 2022
StartActual
Nov 6, 2022
Primary completionEst.
Oct 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05640024
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Nov 6, 2022
Primary completion
Oct 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Dec 7, 2022

Study contacts

Jung-Yun Lee
Contact
jungyunlee@yuhs.ac
82-2-2228-2237
Jung-Yun Lee
principal investigator · Yonsei University College of Medicine Department of Obstetrics and Gynecology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion